Liquidia shares plunge after court upholds patent infringement ruling, prompting analyst downgrades
A Delaware District Court upheld United Therapeutics’ ’327 patent claims 1 and 14, finding Liquidia infringed the patent and casting doubt on its investigational drug L606. Wells Fargo responded by cutting its price target from $108.00 to $30.00 and downgrading the stock to Equal Weight. The shares fell about 59% over the week to roughly $27.99. Liquidia reported Q2 2026 earnings of $0.74 per share, missing the $0.76 estimate, while revenue of $171.68 million slightly beat the $170.98 million forecast.
Why it matters
Wells Fargo says the ruling creates high uncertainty for L606’s market expansion, which could limit future cash flow and justifies the lower price target. Insider net selling of $222.5 million adds further pressure on the stock’s valuation.
Key facts
- 1Wells Fargo cut Liquidia’s price target to $30.00 from $108.00. investing.com
- 2Liquidia’s shares fell 59% over the past week to $27.99. investing.com
- 3A Delaware District Court upheld claims 1 and 14 of United Therapeutics’ ’327 patent against Liquidia. investing.com
- 4Liquidia posted Q2 earnings of $0.74 per share, missing the $0.76 forecast. investing.com
- 5Revenue reached $171.68 million, slightly above the $170.98 million estimate. investing.com
- 6Insiders have sold $222.5 million of Liquidia shares over the past 12 months. gurufocus.com
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.